Equities research analysts expect Dynavax Technologies Co. (NASDAQ:DVAX) to announce $1.66 million in sales for the current quarter, according to Zacks. Two analysts have made estimates for Dynavax Technologies’ earnings. The lowest sales estimate is $1.00 million and the highest is $2.31 million. Dynavax Technologies posted sales of $110,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 1,409.1%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, August 1st.
On average, analysts expect that Dynavax Technologies will report full year sales of $13.28 million for the current fiscal year, with estimates ranging from $7.87 million to $18.68 million. For the next financial year, analysts forecast that the business will post sales of $101.86 million per share, with estimates ranging from $88.31 million to $115.41 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.82 million. Dynavax Technologies had a negative net margin of 31,635.17% and a negative return on equity of 60.61%. The company’s quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.60) EPS.
DVAX has been the topic of several recent analyst reports. Royal Bank of Canada reiterated a “buy” rating and set a $25.00 price objective on shares of Dynavax Technologies in a research report on Friday, March 9th. Cantor Fitzgerald reiterated a “buy” rating and set a $27.00 price objective on shares of Dynavax Technologies in a research report on Tuesday, May 8th. ValuEngine upgraded shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, March 27th. BidaskClub upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, April 16th. Finally, Cowen reiterated a “buy” rating and set a $30.00 price objective on shares of Dynavax Technologies in a research report on Wednesday, February 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $24.67.
Shares of Dynavax Technologies traded up $0.25, hitting $16.15, on Monday, MarketBeat Ratings reports. 2,807,076 shares of the company traded hands, compared to its average volume of 1,386,591. The stock has a market cap of $990.16 million, a P/E ratio of -9.34 and a beta of 0.81. The company has a debt-to-equity ratio of 0.60, a current ratio of 10.85 and a quick ratio of 10.83. Dynavax Technologies has a 52 week low of $7.55 and a 52 week high of $24.45.
In related news, insider Michael S. Ostrach sold 4,000 shares of the business’s stock in a transaction on Friday, June 8th. The shares were sold at an average price of $15.53, for a total value of $62,120.00. Following the sale, the insider now owns 80,554 shares in the company, valued at $1,251,003.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.47% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. WINTON GROUP Ltd bought a new stake in Dynavax Technologies in the first quarter worth $199,000. Xact Kapitalforvaltning AB purchased a new position in Dynavax Technologies during the first quarter worth $200,000. Commonwealth Equity Services LLC purchased a new position in Dynavax Technologies during the first quarter worth $212,000. LPL Financial LLC purchased a new position in Dynavax Technologies during the first quarter worth $283,000. Finally, Paloma Partners Management Co purchased a new position in Dynavax Technologies during the fourth quarter worth $331,000. Institutional investors own 77.60% of the company’s stock.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.